Patents by Inventor Raúl Insa Boronat
Raúl Insa Boronat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11883538Abstract: The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.Type: GrantFiled: July 28, 2017Date of Patent: January 30, 2024Assignee: Som Innovation Biotech, S.L.Inventors: Anna Nardi Ricart, Josep María Suñé Negre, Núria Reig Bolaño, Raúl Insa Boronat, Oscar Huertas Gambín, Santiago Esteva Gras, Gal⋅Ia Pericot Mohr
-
Publication number: 20230218644Abstract: The present invention relates to a compound selected from the group consisting of cynarine, eravacycline and prexasertib or a pharmaceutically acceptable salt thereof, preferably eravacycline or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of viral infections by coronavirus selected from the group consisting of MERS-CoV, SARS-CoV and SARS-CoV-2 virus, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations.Type: ApplicationFiled: April 15, 2021Publication date: July 13, 2023Inventors: Raúl INSA BORONAT, Luca SIGNORILE, Núria REIG BOLAÑO, Dong-Hae SHIN
-
Publication number: 20230147129Abstract: The present invention relates to a compound selected from the group consisting of of N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide, [2-(2,6-dichloroanilino)-4,5-dihydroimidazol-1-yl]-phenylmethanone, 2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one, N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide and 2-(1,4-dioxaspiro[4.5]decan-2-ylmethyl)guanidin, or a pharmaceutically acceptable salt thereof and combinations comprising at least one of said compounds, for use in the treatment and/or prevention of synucleinopathies.Type: ApplicationFiled: March 26, 2021Publication date: May 11, 2023Inventors: Raúl INSA BORONAT, Núria REIG BOLAÑO, Luca SIGNORILE, Oscar HUERTAS GAMBÍN, Salvador VENTURA ZAMORA, Samuel PEÑA DÍAZ
-
Patent number: 11564899Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: GrantFiled: August 28, 2020Date of Patent: January 31, 2023Assignee: SOM Innovation Biotech, S.L.Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
-
Publication number: 20220133726Abstract: The present invention relates to a compound selected from the group consisting of nolatrexed, triamterene, sultopride and hydrastinine or a pharmaceutically acceptable salt thereof, preferably triamterene, nolatrexed or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of phenylketonuria, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations.Type: ApplicationFiled: February 13, 2020Publication date: May 5, 2022Inventors: Raúl INSA BORONAT, Núria REIG BOLAÑO, Aileen FERRÉ FERRÉ, Óscar HUERTAS GAMBÍN, Santiago ESTEVA GRAS, Luca SIGNORILE, Gal.la PERICOT MOHR
-
Publication number: 20200390733Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: ApplicationFiled: August 28, 2020Publication date: December 17, 2020Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
-
Patent number: 10786473Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: GrantFiled: September 12, 2019Date of Patent: September 29, 2020Assignee: SOM Innovation Biotech, S.L.Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
-
Publication number: 20200138760Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: ApplicationFiled: September 12, 2019Publication date: May 7, 2020Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
-
Patent number: 10449169Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: GrantFiled: August 13, 2018Date of Patent: October 22, 2019Assignee: SOM Innovation Biotech, S.L.Inventors: Marc Centellas Casado, Raúl Insa Boronat, Núria Reig Bolano, Nuria Gavaldà Batalla
-
Publication number: 20190167596Abstract: The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.Type: ApplicationFiled: July 28, 2017Publication date: June 6, 2019Inventors: Anna Nardi Ricart, Josep María Suñé Negre, Núria Reig Bolaño, Raúl Insa Boronat, Oscar Huertas Gambín, Santiago Esteva Gras, Gal·la Pericot Mohr
-
Publication number: 20190091188Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: ApplicationFiled: August 13, 2018Publication date: March 28, 2019Inventors: Marc Centellas Casado, Raúl Insa Boronat, Núria Reig Bolano, Nuria Gavaldà Batalla
-
Patent number: 10045956Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: GrantFiled: March 2, 2017Date of Patent: August 14, 2018Assignee: SOM Innovation Biotech, S.L.Inventors: Marc Centellas Casado, Raúl Insa Boronat, Núria Reig Bolano, Nuria Gavaldà Batalla
-
Publication number: 20180042869Abstract: (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.Type: ApplicationFiled: September 22, 2017Publication date: February 15, 2018Inventors: Nuria GAVALDA BATALLA, Raul INSA BORONAT, Nuria REIG BOLANO
-
Publication number: 20170304243Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: ApplicationFiled: March 2, 2017Publication date: October 26, 2017Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolano, Núria Gavaldà Batalla
-
Patent number: 9789072Abstract: (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.Type: GrantFiled: June 18, 2014Date of Patent: October 17, 2017Assignee: SOM INNOVATION BIOTECH, S.L.Inventors: Nuria Gavalda Batalla, Raul Insa Boronat, Nuria Reig Bolano
-
Patent number: 9610270Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: GrantFiled: October 23, 2012Date of Patent: April 4, 2017Assignee: SOM INNOVATION BIOTECH, S.L.Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
-
Publication number: 20160158167Abstract: (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyllamine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.Type: ApplicationFiled: June 18, 2014Publication date: June 9, 2016Inventors: Nuria GAVALDA BATALLA, Raul INSA BORONAT, Nuria REIG BOLANO
-
Publication number: 20140296188Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: ApplicationFiled: October 23, 2012Publication date: October 2, 2014Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
-
Patent number: 8658599Abstract: A method to inhibit the formation of skin tumors at early stages and their subsequent progression to carcinoma in a mammal is described, the method including the topical application to the mammal's skin of a composition that includes a therapeutically effective amount of disitertide, together with pharmaceutically acceptable carriers or diluents.Type: GrantFiled: March 4, 2010Date of Patent: February 25, 2014Assignee: Digna Biotech, S.L.Inventors: Raul Insa Boronat, Miguel Quintanilla Avila, Javier Dotor De Las Herrerías
-
Publication number: 20120065144Abstract: It comprises an inhibitor peptide of TGF-?1 for use in preventive or therapeutic treatment of skin tumors at early stages, in which the peptide is disitertide or a derivate thereof, and a pharmaceutical composition that comprises a therapeutically effective amount of the peptide.Type: ApplicationFiled: March 4, 2010Publication date: March 15, 2012Applicant: ISDIN, S.A.Inventors: Raul Insa Boronat, Miguel Quintanilla Avila, Javier Dotor De Las Herrerias